drug
as of 2026-07-01LB-102
LB-102 (50 mg tablet)LB-102 (100 mg tablet)
at a glance
small molecule
Pre-approval / investigational in the US
Developed by LB Pharmaceuticals Inc.
Issued protection wall to 2037 (CoM + MoT (core))
5 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Patent estate
pre-approval · family-level, issued vs pending
CoM + MoT (core)2037issued
18 issued · 7 pending — The CORE wall: composition-of-matter + method-of-treatment for schizophrenia. Issued in US (5) + 13 foreign. This is the strongest protection and the earliest expiry (2037).
MoT (broad indications)2042pending
0 issued · 13 pending — All-pending method-of-treatment family extending coverage to 2042. No issued patents yet — protection contingent on grant.
MoT (Poor Cognition)2044pending
0 issued · 2 pending — Cognition-focused method-of-use (maps to CIAS expansion opportunity). Early-stage: 1 PCT + 1 Taiwan application.
MoT (2046)2046pending
0 issued · 3 pending — Later method-of-treatment family to 2046; includes a US provisional (earliest-stage filing).
CoM (2047)2047pending
0 issued · 1 pending — A SECOND composition-of-matter family projected to 2047 — if granted, extends the strongest protection type a full decade past the core 2037 wall. Currently a single US provisional (earliest, least-certain stage).
Trials
5
52-week Open Label Safety-Tolerability Study
NCT07369154Phase 3Not Yet Recruiting
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
NCT07363577Phase 3Recruiting
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
NCT06179108Phase 2Completed
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
NCT04588129Phase 1Completed
Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults
NCT04187560Phase 1Completed
KOLs & investigators
3
Publications & congress
30
LB-102 for Acute Schizophrenia in Adults: Results From the Phase 2 NOVA-1 Clinical Trial, With a Focus on PANSS Marder Factor Scores
2026 · congress · high-value
LB-102 for Acute Schizophrenia in Adults: Results From the Phase 2 NOVA-1 Clinical Trial, With a Focus on PANSS Marder Factor Scores
2026 · congress · high-value
LB-102 for Acute Schizophrenia in Adults: Results From the Phase 2 NOVA-1 Clinical Trial, With a Focus on PANSS Marder Factor Scores
2026 · congress · high-value
LB-102 for Acute Schizophrenia in Adults: Results From the Phase 2 NOVA-1 Clinical Trial, With a Focus on PANSS Marder Factor Scores
2026 · congress · high-value
LB-102 for cognition in patients with schizophrenia: an exploratory post hoc analysis from a randomised, double-blind, placebo-controlled phase 2 study
2026 · congress · high-value
LB-102 for cognition in patients with schizophrenia: an exploratory post hoc analysis from a randomised, double-blind, placebo-controlled phase 2 study
2026 · congress · high-value
LB-102 for cognition in patients with schizophrenia: an exploratory post hoc analysis from a randomised, double-blind, placebo-controlled phase 2 study
2026 · congress · high-value
LB-102 for cognition in patients with schizophrenia: an exploratory post hoc analysis from a randomised, double-blind, placebo-controlled phase 2 study
2026 · congress · high-value
LB-102 for cognition in patients with schizophrenia: an exploratory post hoc analysis from a randomised, double-blind, placebo-controlled phase 2 study
2026 · congress · high-value
LB-102 for Acute Schizophrenia in Adults: Results From the Phase 2 NOVA-1 Clinical Trial, With a Focus on PANSS Marder Factor Scores
2026 · congress · high-value
LB-102 for cognition in patients with schizophrenia: an exploratory post hoc analysis from a randomised, double-blind, placebo-controlled phase 2 study
2026 · congress · high-value
LB-102 for Acute Schizophrenia in Adults: Results From the Phase 2 NOVA-1 Clinical Trial, With a Focus on PANSS Marder Factor Scores
2026 · congress · high-value
LB-102 for Acute Schizophrenia in Adults: Results From the Phase 2 NOVA-1 Clinical Trial, With a Focus on PANSS Marder Factor Scores
2026 · congress · high-value
LB-102 for cognition in patients with schizophrenia: an exploratory post hoc analysis from a randomised, double-blind, placebo-controlled phase 2 study
2026 · congress · high-value
LB-102 for acute schizophrenia in adults: Results from the phase 2 clinical trial (NOVA1) with a focus on Negative Symptoms
2025 · congress · high-value
LB-102 for Acute Schizophrenia in Adults: Efficacy and Safety From a Large Phase 2 Clinical Trial
2025 · congress · high-value
Facts & assertions
10 sourced
Composition Of Matter Core ExpiryThe decisive wall: issued composition-of-matter + method-of-treating-schizophrenia patents expire 2037 (before PTA/PTE). With Hatch-Waxman PTE (up to 5 yrs, company expects up to 5), effective CoM protection could reach ~2042 depending on approval/launch timing.
2,037
Global Rights Retained Us CommercializationLB holds global rights to LB-102; intends to retain US commercialization while evaluating ex-US collaborations (per 10-K).
yes
Hatch Waxman Pte Expected YearsCompany expects patent term extension up to 5 years (Hatch-Waxman) once approved — but only ONE patent extendable, first-approved-use only. Applies to the 2037 CoM patent in practice.
5
Lai Formulation In DevelopmentLB-102 long-acting injectable (LAI) formulation in development — addresses adherence (a NICE/APA-cited priority). Future pipeline optionality.
yes
Lai Lifecycle Protection StrategyLAI formulation in development (Source 10) is also a patent-lifecycle play: a granted LAI/formulation patent would extend commercial protection beyond the 2037 CoM wall via a new exclusivity layer.
yes
Open Ring Derivative PatentsLB also owns 2 US patents on open-ring derivative compounds of LB-102 (CoM + methods) — defensive/next-gen coverage beyond the lead molecule.
2
Patent Estate Expiry RangeLayered families project 2037 (issued CoM) -> 2042 -> 2044 -> 2046 -> 2047 (later CoM, still provisional). Later walls are PENDING/provisional — real only if granted. Honest read: firm protection to 2037(+PTE); 2042-2047 is aspirational estate-building.
low: 2,037; high: 2,047
Patent Estate Total~51 patents + pending applications (US + foreign) as of 2026-03-01: 7 issued US, 14 issued foreign, rest pending. 43 relate directly to LB-102.
51
R Enantiomer Patents FiledPatents/applications directed to the R-enantiomer of LB-102 (China issued; HK/EPO/Taiwan/China pending) — lifecycle & defensive filing to block enantiomer work-arounds.
yes
Second Composition Of Matter Family 2047A second CoM family projected to 2047 exists but is a single US provisional — earliest, least-certain stage. If granted, materially extends the franchise; not bankable yet.
yes
relationships
The graph out of here
developer
company
trial
trial
trial
indication
indication
indication
KOL
John M Kane, MD
personKOL score 19
Dean Wong, MD,PhD
personKOL score 11
Lukasz Biernat, PhD
personKOL score —